The purpose of our work group is to promote inclusion and equity within cardiology and to engage with clinicians to increase education to our cardiology colleagues about awareness of cardiovascular ...

News and announcements from the Imaging Section. Join Vivek Kulkarni, MD, FACC, on Friday, March 28 from 1-5 p.m. CT, for a pre-conference workshop designed for navigating the world of research and ...

Apply Now For GLI 2026. The Wael Al Mahmeed Global Leadership Institute (GLI) brings together a group of 30 early- to mid-career cardiology professionals from across the globe to participate in a ...

A new ACC Scientific Statement addresses the management of obesity in adults with heart failure (HF), with a specific focus on those with stage 2 HF with preserved ejection fraction (HFpEF). It is the ...

Discover cutting-edge insights in sports cardiology at Care of the Athletic Heart, taking place June 12 – 14, 2025, in Washington, DC, or virtually!Plan to join Course Chairs Meagan Wasfy, MD, MPH, ...

Patients undergoing transcatheter left atrial appendage occlusion (LAAO) with the Watchman FLX had significantly lower risk of major adverse events and ischemic stroke at one year vs. patients ...

The cardiovascular medicine workforce is facing a critical shortage that threatens to undermine patient care in the U.S. A recent article published in Cardiology magazine discusses reasons for the ...

JACC: Case Reports is looking to highlight interesting surgical cases, including case reports, case series, viewpoints, first-in-human/early reports and more in an upcoming issue.Authors are ...

Although hospitals in the U.S. acquired by private equity had a significant decline in the clinical risk of patients admitted, there was no improvement in outcomes among older adults with heart ...

In patients with atrial fibrillation (AFib) randomized to abelacimab vs. rivaroxaban, no statistically significant differences in bleeding risk were observed, suggesting that interruption of ...

Patients undergoing transseptal mitral valve-in-valve (MViV) replacement with preprocedural severe or greater tricuspid regurgitation (TR), 30-day residual severe or greater TR, and unchanged or ...